Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.48 |
| ▸ | BAZ2A | Q9UIF9 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | BRD2 | P25440 | 1/20 | 0.48 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496758 | 0.84 | NPC1 (0.60) | NPC1RAB9AEPHB3ADORA2ANPSR1 | |
| SCHEMBL2017759 | 0.82 | NPC1 (0.59) | NPC1RAB9AEPHB3ADORA2ANPSR1 | |
| Hydrochloric Acid SCHEMBL21834227 | 0.82 | NPC1 (0.59) | NPC1RAB9AEPHB3ADORA2ANPSR1 | |
| SCHEMBL14743372 | 0.82 | NPC1 (0.63) | NPC1RAB9AEPHB3ADORA2ANPSR1 | |
| SCHEMBL15670582 | 0.81 | NPC1 (0.55) | NPC1RAB9AEPHB3ADORA2ANPSR1 | |
| SCHEMBL2498113 | 0.81 | NPC1 (0.55) | NPC1RAB9AEPHB3ADORA2ANPSR1 | |
| SCHEMBL948693 | 0.81 | NPC1 (0.58) | NPC1RAB9AEPHB3ADORA2ANPSR1 | |
| SCHEMBL12789990 | 0.81 | RAB9A (0.55) | NPC1RAB9AEPHB3ADORA2ANPSR1 | |
| SCHEMBL14707153 | 0.81 | NPC1 (0.55) | NPC1RAB9AEPHB3ADORA2ANPSR1 | |
| SCHEMBL9913664 | 0.81 | EPHB3 (0.62) | NPC1RAB9AEPHB3ADORA2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240166643-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2024-05-23 | — | — | US | disclosed |
| EP-4214205-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | Imperial College Innovations Limited (GB) | 2023-07-26 | — | — | EP | disclosed |
| CN-116157122-A | Imidazo [1,2-a ] pyridine compounds and their use in therapy | 帝国理工学院创新有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2022058745-A9 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022058745-A9 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022058745-A2 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022058745-A2 | NOVEL COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2022-03-24 | — | — | WO | disclosed |
| US-20190330189-A1 | ANTIBACTERIAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-31 | — | — | US | disclosed |
| WO-2002066480-A2 | 2-ARYLAMINO-PYRIMIDINES FOR THE TREATMENT OF GSK3-RELATED DISORDERS | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002065979-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
| EP-1214318-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001014375-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-01 | — | — | WO | disclosed |
| EP-0235752-B1 | Piperidine derivative, pharmaceutical composition containing the same and use | EISAI CO LTD (JP) | 1993-11-18 | — | — | EP | disclosed |
| US-5179095-A | Antiarrhythmia agents | EISAI CO., LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| US-5118689-A | Antiarrhythmia agents | EISAI CO., LTD. (JP) | 1992-06-02 | — | — | US | disclosed |
| US-4996215-A | Antiarrythmia agents | EISAI CO., LTD. (JP) | 1991-02-26 | — | — | US | disclosed |
| US-4876262-A | ANTIARRHYTHMIA AGENTS | EISAI CO., LTD. (JP) | 1989-10-24 | — | — | US | disclosed |
| EP-0235752-A2 | Piperidine derivative, pharmaceutical composition containing the same and use | Eisai Co., Ltd. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166643-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | ABL1, TPMT, IDH2 | NPC1 1139/4885RAB9A 1943/4885EPHB3 1786/4885 |
| US-20190330189-A1 | ANTIBACTERIAL COMPOUNDS | FDPS, SQOR, NDUFS3 | NPC1 1147/4885RAB9A 3094/4885EPHB3 4692/4885 |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | OGFR, CBR3, CBR1 | NPC1 213/4885RAB9A 3184/4885EPHB3 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.